A critique of therapeutic trials in Helicobacter pylori-positive functional dyspepsia

Gastroenterology

Volumn 106, Issue 5, 1994, Pages 1174-1183

  Talley, Nicholas J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; BISMUTH CITRATE; BISMUTH SALICYLATE; CLINDAMYCIN; ERYTHROMYCIN; FURAZOLIDONE; METRONIDAZOLE; NITROFURANTOIN; PLACEBO;

ANTIMICROBIAL ACTIVITY; ARTICLE; CROSSOVER PROCEDURE; DISEASE CONTROL; DRUG EFFICACY; DRUG MIXTURE; DRUG SENSITIVITY; DYSPEPSIA; FOLLOW UP; GASTRITIS; HELICOBACTER PYLORI; HUMAN; PATIENT COMPLIANCE; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZATION; TREATMENT PLANNING;

EID: 0028334872     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/0016-5085(94)90007-8     Document Type: Article

References (61)

1. Functional dyspepsia: a classification with guidelines for diagnosis and management
2. Definitions of dyspepsia
3. Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy
4. The role of Helicobacter pylori in nonulcer dyspepsia: a debate—against
5. The role of Helicobacter pylori in nonulcer dyspepsia: a debate—for
6. Prevalence of Helicobacter pylori and histologic gastritis in asymptomatic persons
7. Is Helicobacter pylori the cause of dyspepsia?
8. Drug treatment of functional dyspepsia
9. Campylobacter pyloridis and associated gastritis: investigator blind placebo-controlled trial of bismuth salicylate and erythromycin ethyl-succinate
10. Non-ulcer dyspepsia and short-term De-Nol therapy: a placebo controlled trial with particular reference to the role of Campylobacter pylori
11. Campylobacter pylori—a role in non-ulcer dyspepsia?
12. Campylobacter associated gastritis in patients with non-ulcer dyspepsia: a double blind placebo controlled trial with colloidal bismuth subcitrate
13. Effect of colloidal bismuth subcitrate on symptoms and gastric histology in non-ulcer dyspepsia. A double-blind placebo controlled study
14. Helicobacter pylori infection and non-ulcer dyspepsia: the effect of treatment with colloidal bismuth subcitrate
15. A placebo controlled trial of bismuth salicylate in Helicobacter pylori associated gastritis
16. Double blind trial of colloidal bismuth subcitrate versus placebo in Helicobacter pylori positive patients with non-ulcer dyspepsia
17. Bismuth subsalicylate suppression of Helicobacter pylori in nonulcer dyspepsia: a double-blind placebo-controlled trial
18. Campylobacter pylori associated gastritis: a double-blind placebo-controlled trial with amoxycillin
19. Nitrofurans in the treatment of gastritis associated with Campylobacter pylori
20. Eradicating Helicobacter pylori and symptoms of non-ulcer dyspepsia
21. Double-blind randomized trial of bismuth subsalicylate and clindamycin for treatment of Helicobacter pylori infection
22. Helicobacter pylori clearance in the treatment of non-ulcer dyspepsia
23. Evaluation of therapies in the treatment of Helicobacter pylori associated non-ulcer dyspepsia
24. Are routine duodenal and antral biopsies useful in the management of “functional” dyspepsia? A diagnostic and therapeutic study
25. Is gastroduodenitis a cause of chronic dyspepsia?
26. Epidemiologic methods in clinical trials
27. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States: effect of age, race, and socioeconomic status
28. Helicobacter pylori infection rates in relation to age and social class in a population of Welsh men
29. The irritable bowel syndrome: toward optimal design of controlled treatment trials
30. The two-period cross-over clinical trial
31. A controlled trial of psychological treatment for the irritable bowel syndrome
32. “Prokinetic” treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride
33. Controlled treatment trials in the irritable bowel syndrome: a critique
34. Gastric emptying, esophageal 24-hour pH and gastric potential difference measurements in non-ulcer dyspepsia
35. 2-receptor antagonists
36. Advances in the understanding of the mechanism of cytoprotective action by colloidal bismuth subcitrate
37. Colloidal bismuth subcitrate inhibits peptic degradation of gastric mucus and epidermal growth factor in vitro
38. Can severity of symptoms be used as outcome measures in trials of non-ulcer dyspepsia and Helicobacter pylori associated gastritis?
39. A technique for the development of attitude scales
40. Self-rating of pain in non-ulcer dyspepsia A methodological study comparing a new fixed-point scale and the visual analogue scale
41. Measuring health-related quality of life
42. Quality of life in patients with upper gastrointestinal symptoms An improved evaluation of treatment regimens?
43. Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia
44. Patient compliance in therapeutic trials
45. Factors influencing the eradication of Helicobacter pylori with triple therapy
46. Omeprazole plus amoxicillin: efficacy of various treatment regimens to eradicate Helicobacter pylori
47. Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study
48. Understanding and improving patients compliance
49. Prognosis of chronic unexplained dyspepsia: a prospective study of potential predictor variables in patients with endoscopically diagnosed non-ulcer dyspepsia
50. Disappearance of gastritis after eradication of Helicobacter pylori: a morphometric study
51. The Sydney system: a new classification of gastritis. Introduction
52. 13C-urea breath test
53. 14C]Urea breath test for diagnosis of Helicobacter pylori
54. Seroconversion for Helicobacter pylori
55. The importance of beta, the type II error and sample size in the design and interpretation of the randomized controlled trial: survey of 71 “negative” trials
56. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders
57. Some thoughts on clinical trials, especially problems of multiplicity
58. Controversy in counting and attributing events in clinical trials